TY - JOUR T1 - COVID-19 causing HELLP-like syndrome in pregnancy and role of angiogenic factors for differential diagnosis JF - medRxiv DO - 10.1101/2020.07.10.20133801 SP - 2020.07.10.20133801 AU - Francesc Figueras AU - Elisa Llurba AU - Raigam Martinez-Portilla AU - Josefina Mora AU - Fatima Crispi AU - Eduard Gratacos Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/11/2020.07.10.20133801.abstract N2 - Importance The clinical presentation of hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome is one of the more severe forms of preeclampsia. COVID-19 infection exhibits signs that are shared with preeclampsia and HELLP syndrome, which may lead to needless interventions and iatrogenic preterm delivery.Objective We evaluated the prevalence of HELLP-like signs in pregnant women admitted for COVID-19 and the value of angiogenic factors to rule out preeclampsia.Methods a consecutive series of 27 pregnant women beyond 20 weeks of gestation, with symptomatic COVID-19. Clinical and analytical features were recorded and those cases with signs of HELLP syndrome were tested for sFlt-1/PlGF ratio.Results Seven patients (25.9%) presented at least one sign of suspected HELLP syndrome, of which 2 (7.4%) were diagnosed clinically with PE because of hypertension and high transaminases and 5 (18.5%) had only elevated transaminases. sFlt-1/PlGF ratio was normal in 6 of 7.Conclusion Symptomatic COVID-19 may simulate severe preeclampsia in pregnancy. Angiogenic factors may be essential to avoid false diagnosis and needless interventions.Question Do pregnant women with symptomatic COVID-19 infection exhibit signs shared with preeclampsia and HELLP syndrome? Are these conditions ruled out by the measurement of angiogenic factors?Findings In series of 27 pregnancies with symptomatic COVID-19 infection, 7 presented at least one sign of suspected HELLP syndrome. In 6 of them, the level of angiogenic factors ruled out preeclampsia.Meaning Symptomatic COVID-19 may simulate severe pregnancy in pregnancy. Angiogenic factors may be essential to avoid false diagnosis and needless interventions.These data were presented in a Virtual Symposium on Covid-19 and Pregnancy on 17 April: 2020:(http://medicinafetalbarcelona.org/simposiocovid19/ [Spanish] and https://medicinafetalbarcelona.org/symposiumcovid19/ [English]Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding involvedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of Hospital Sant Joan de Deu (PIC-56-20).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in the manuscript are available on personal demand ER -